Legend Biotech (LEGN)
23.53
0.00 (0.00%)
Upcoming Events
Latest Headlines
H.C. Wainwright Reiterates Buy Rating on Legend Biotech Corp. (LEGN)
July 16, 2026 6:48 AM - StreetInsider
Form 6-K Legend Biotech Corp For: Jul 15
July 15, 2026 7:30 AM - SEC Filing
JPMorgan Resumes Legend Biotech Corp. (LEGN) at Neutral
July 13, 2026 3:13 AM - StreetInsider
Legend Biotech Corp. (LEGN) PT Lowered to $63 at RBC Capital
July 7, 2026 8:00 AM - StreetInsider
Form 4 Legend Biotech Corp For: Jun 30 Filed by: Casey Patrick John
July 2, 2026 4:06 PM - SEC Filing
Form 4 Legend Biotech Corp For: Jun 30 Filed by: Huang Ying
July 2, 2026 4:06 PM - SEC Filing
Form 144 Legend Biotech Corp Filed by: Casey Patrick John
June 30, 2026 10:47 AM - SEC Filing
Form 4 Legend Biotech Corp For: Jun 25 Filed by: Huang Ying
June 29, 2026 9:53 PM - SEC Filing
Form 144 Legend Biotech Corp Filed by: Huang Ying
June 26, 2026 3:23 PM - SEC Filing
Calidi Biotherapeutics adds biopharma veteran Corsee Sanders to board
June 23, 2026 8:00 AM - StreetInsider
Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors
June 23, 2026 8:00 AM - StreetInsider
Form 6-K Legend Biotech Corp For: Jun 22
June 22, 2026 4:20 PM - SEC Filing
Form 424B5 Legend Biotech Corp
June 18, 2026 4:37 PM - SEC Filing
Legend Biotech prices $226 million public offering of ADS shares
June 17, 2026 9:22 PM - StreetInsider
Legend Biotech Corporation Announces Pricing of Public Offering
June 17, 2026 9:21 PM - Globe NewsWire
Form 424B5 Legend Biotech Corp
June 17, 2026 4:50 PM - SEC Filing
Form F-6EF Legend Biotech Corp Filed by: JPMorgan Chase Bank, N.A. - ADR Depositary
June 17, 2026 4:43 PM - SEC Filing
Legend Biotech launches $225 million ADS public offering
June 17, 2026 4:29 PM - StreetInsider
Legend Biotech Corporation Announces Proposed Public Offering
June 17, 2026 4:29 PM - Globe NewsWire
Form 6-K Legend Biotech Corp For: Jun 15
June 15, 2026 8:00 AM - SEC Filing
Legend Biotech reports early trial results for in vivo CAR-T therapy
June 15, 2026 8:00 AM - StreetInsider
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
June 15, 2026 8:00 AM - StreetInsider
Legend Biotech reports early clinical trial results for LB2501 therapy
June 14, 2026 8:12 AM - StreetInsider
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
June 14, 2026 3:15 AM - StreetInsider
Legend Biotech Corp. (LEGN) PT Raised to $49 at UBS
June 3, 2026 6:50 AM - StreetInsider
Form 6-K Legend Biotech Corp For: Jun 02
June 2, 2026 9:30 AM - SEC Filing
Legend Biotech to present LB2501 in vivo CAR-T data at EHA conference
June 2, 2026 9:30 AM - StreetInsider
Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL)
June 2, 2026 9:30 AM - StreetInsider
Legend Biotech presents early solid tumor data for LB2102 at ASCO 2026
June 1, 2026 10:00 AM - StreetInsider
Form 6-K Legend Biotech Corp For: Jun 01
June 1, 2026 10:00 AM - SEC Filing
Legend Biotech Presents First-in-Human LB2102 Results in Solid Tumors and New CARVYKTI® Data in Multiple Myeloma at ASCO 2026
June 1, 2026 10:00 AM - StreetInsider
RBC Capital on Legend Biotech Corp. (LEGN): 'We remain buyers'
June 1, 2026 7:48 AM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on Legend Biotech Corp. (LEGN)
June 1, 2026 6:58 AM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on Legend Biotech Corp. (LEGN)
May 27, 2026 6:45 AM - StreetInsider
Form 6-K Legend Biotech Corp For: May 21
May 21, 2026 5:00 PM - SEC Filing
Legend Biotech Announces Presentations at ASCO 2026
May 21, 2026 5:00 PM - Globe NewsWire
Legend Biotech Corp. (LEGN) PT Lowered to $48 at Morgan Stanley
May 13, 2026 8:19 AM - StreetInsider
Legend Biotech Corp. (LEGN) PT Raised to $29 at TD Cowen
May 13, 2026 7:50 AM - StreetInsider
Legend Biotech Corp. (LEGN) PT Raised to $64; RBC Capital: 'We see opportunity for share appreciation'
May 13, 2026 7:29 AM - StreetInsider
Legend Biotech (LEGN) Misses Q1 EPS by 16c
May 12, 2026 7:30 AM - StreetInsider
Form 6-K Legend Biotech Corp For: Mar 31
May 12, 2026 7:07 AM - SEC Filing
Legend Biotech Reports First Quarter 2026 Results and Recent Highlights
May 12, 2026 7:00 AM - Globe NewsWire
Legend Biotech Expands Scientific Advisory Expertise to Inform Future Growth
May 4, 2026 8:00 AM - StreetInsider
Legend Biotech to Host Investor Conference Call on First Quarter 2026 Results
April 28, 2026 8:01 AM - Globe NewsWire
Full Article List
